mRNA therapeutics Market Research Report

Report Overview

The market for mRNA therapies was estimated to be worth USD 39.90 billion in 2021 and is anticipated to increase at a CAGR of 1.7% from 2022 to 2030. Because of its excellent potential for treating chronic diseases, RNA-based therapies have received a lot of interest in recent years. The production, distribution, and safety of RNA vaccines are also vastly superior to those of DNA vaccines. While mRNA treatments and vaccines have shown potential in human clinical studies, demand for them has increased. Also, a significant rise in the quantity of mRNA-based vaccine therapies being investigated in oncology clinical trials can be attributed to the success of the COVID-19 vaccines created by Moderna and Pfizer-BioNTech. Also, 2021 saw the second-highest number of mRNA vaccination trials for cancer patients after the COVID-19 trials in cancer patients, which fueled the industry’s expansion.

The COVID-19 pandemic has positively impacted the expansion of the worldwide market because of the expanding number of COVID-19 patients around the world and the large external financing for the production of mRNA-based COVID-19 vaccines. Also, because mRNA vaccines offer strong defence against new strains of the SARS-COVID-19 virus, demand for them surges when they arrive in several countries throughout the world. Because of this, it is anticipated that during the COVID-19 pandemic, demand for these mRNA-based treatments would rise and the market will expand.

A prospective therapeutic tool, messenger RNAs have additionally evolved as a result of recent technological developments in translation, delivery, and better stability. In fact, mRNA vaccines have opened up fresh pharmacological frontiers and become a significant therapeutic subclass. A new era in vaccine development has begun with the assistance of these mRNA vaccines for next-generation vaccinations. For instance, Moderna, Inc. and the National Institute of Allergy and Infectious Diseases created the mRNA-1273 in collaboration in March 2020. (NIAID). It exhibits 94.1% efficacy in symptomatic COVID-19 prophylaxis, and in December 2020, the US Food & Drug Administration (US FDA) granted emergency use authorization for broad immunisation of humans. Moreover, mRNA treatments, a fast expanding class of drugs for many diseases, will revolutionise personalised medicine and change the established standard of care. The market for products based on mRNA is therefore predicted to increase in the upcoming years.

Application Insights

In 2021, the infectious disease category dominated the market and accounted for all of the revenue. The market is expected to be driven by the rising use of mRNA-based vaccines, a large number of candidates beginning clinical trials for various infectious diseases, and the COVID-19 outbreak in late 2019. Over the course of the projected period, the oncology section is anticipated to grow at a profitable pace. According to predictions from the World Health Organization (WHO), 10 million people will die from cancer worldwide in 2020, making it the leading cause of death.

Additionally, some of the common malignancies that result in death are breast, liver, stomach, rectum, lung, colon, and others. The market will be driven by the requirement for mRNA cancer vaccines and therapeutics as a result of increased chronic illness incidence over the forecast period. Furthermore, the lack of precise cancer therapy drugs is putting pressure on the government and a number of significant firms to make significant investments in R&D. The industry will be driven by the increased demand for cancer vaccines and therapies throughout the forecast period.

Type Insights


In 2021, the preventive vaccinations sector completely controlled the market. Prophylactic vaccinations are the focus of current R&D efforts, according to the report in Nature, with 77% of mRNA firms having at least one preventative vaccine under development. Other vaccines for disorders including influenza and respiratory syncytial virus also contribute to the category growth, but COVID-19 products currently account for the vast bulk of preventive vaccine revenues.

The expansion of the market is further impacted by rising mergers and alliances as well as increased R&D activities by pharmaceutical companies to enhance various preventative vaccination types. As an illustration, Pfizer and Valneva announced the completion of an equity investment for the research and marketing of preventative vaccinations for infectious illnesses in June 2022.

End-use Insights

Around 60.0% of the revenue was generated by the hospitals and clinics segment in 2021, and this segment is anticipated to grow at the fastest rate over the projected period. The market for personalised pharmaceuticals is expanding as a result of the increased use of treatments and vaccines to treat a variety of chronic conditions. The growing number of patients visiting hospitals and clinics is another factor driving this market segment.

The market is also anticipated to develop as more people contract cancer, the flu, infectious disorders, and respiratory problems. In 2019, the WHO estimates that up to 500,000 individuals might pass away from influenza every year and that almost one billion people would be ill, which will probably result in an increase in the need for hospitals and other healthcare facilities. This is just one example from the NCBI study.

Regional Insights

With a market share of approximately 35.0% in 2021, North America was the market’s dominant region and would have the quickest growth throughout the projected period. The presence of significant research funding, growing federal programmes for RNA-based medicines, and an increase in clinical trials will drive the market in North America. For instance, the National Institutes of Health (NIH), the Department of Defence, and federally funded academic laboratories supported Graham and colleagues’ fundamental research in November 2020. This support had a significant role in the quick development of COVID-19 vaccines. Since the epidemic started, the government has provided vaccine manufacturers an additional $10.5 billion to expedite the supply of their products.

Due to a rise in patients and awareness of rare genetic illnesses, Europe accounted for the second-largest revenue share in 2021. Also, there are significant firms operating in Europe, and the demand for mRNA vaccines and therapies to develop transformative treatments is rising there. For instance, Moderna is spreading its wings across Europe (Denmark, Belgium, the Netherlands, Poland, Norway, and Sweden) as part of the U.S. biotech’s expansion to “enable the delivery of mRNA vaccines and therapies locally,” which will boost the demand for mRNA vaccines and further propel the market during the forecast period.

Key Companies & Market Share Insights


To increase their market position, key firms are using a variety of methods, such as alliances, mergers and acquisitions, geographic growth, and strategic collaborations. For instance, a four-year exclusive research collaboration between Pfizer Inc. and Beam Therapeutics Inc. will centre on in vivo base-editing programmes for three targets for uncommon genetic disorders of the muscle, liver, and central nervous system. In a four-year research collaboration, Pfizer and Beam will work on projects involving messenger RNA (mRNA), gene therapy, and lipid nanoparticles. Beam is an expert in base editing and mRNA/LNP delivery technology (LNP). In the global market for mRNA therapies, some notable participants are:

  • Moderna, Inc.
  • BioNTech SE
  • CureVac N.V.
  • Arcturus Therapeutics
  • Translate Bio, Inc.
  • GSK plc.
  • Argos Therapeutics Inc.
  • Sangamo Therapeutics, Inc.
  • Pfizer Inc.
  • AstraZeneca plc.
  • CRISPR Therapeutics AG

Global mRNA Therapeutics Market Segmentation


In addition to providing an analysis of the most recent market trends and prospects in each of the sub-segments from 2020 to 2030, this research projects revenue growth at the global, regional, and national levels. The global mRNA therapeutics market report has been categorised by application, type, end-use, and region for the purposes of this report by Flair Insights:

  • Application Overview (USD Million, 2020 – 2030)
    • Rare Genetic Diseases
    • Oncology
    • Respiratory Diseases
    • Infectious Diseases
    • Others
  • Type Overview (USD Million, 2020 – 2030)
    • Prophylactic Vaccines
    • Therapeutic Vaccines
    • Therapeutic Drugs
  • End-use Overview (USD Million, 2020 – 2030)
    • Hospitals & Clinics
    • Research Organizations
    • Others
  • Regional Overview (USD Million, 2020 – 2030)
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE